<DOC>
	<DOC>NCT02138136</DOC>
	<brief_summary>A study of the long-term safety and efficacy of Lubiprostone in subjects aged ≥ 6 to &lt; 18 years diagnosed with Functional Constipation</brief_summary>
	<brief_title>Long-term Safety and Efficacy of Lubiprostone in Subjects Aged ≥ 6 Years to &lt; 18 Years With Functional Constipation</brief_title>
	<detailed_description>The purpose of this study is to assess the long-term safety, efficacy, and pharmacokinetics of oral lubiprostone 12 or 24 mcg capsules dosed twice daily (BID) when administered orally for 36 weeks in paediatric subjects with functional constipation.</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Completed 12 weeks of blinded treatment in the SAG/0211PFC1131 study. Continue to abstain from taking concomitant medication (prescribed or overthecounter) that affects gastrointestinal motility. Untreated faecal impaction at the time of rolling over into study. Significant change in medical status, newly diagnosed and uncontrolled cardiovascular, liver or lung disease, neurologic or psychiatric disorder, or other systemic disease. Demonstrated noncompliance with study protocol during the SAG/0211PFC1131 study.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>